Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds. ##STR00001##

Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds. ##STR00001##

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

##STR00001##

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

##STR00001##

A compound, a solid carrier including the same and a method for preparing a nucleic acid are provided. The compound has a structure represented by Formula (1) as follows.

##STR00001##

In Formula (1), the definition of Y.sup.1, Y.sup.2, Z and * are the same as defined in the detailed description.

A compound, a solid carrier including the same and a method for preparing a nucleic acid are provided. The compound has a structure represented by Formula (1) as follows.

##STR00001##

In Formula (1), the definition of Y.sup.1, Y.sup.2, Z and * are the same as defined in the detailed description.

The invention covers new bicyclic bridged [1,3]oksazepine derivatives of the general formula (I) and (II):

##STR00001##

which exhibit enhanced photochromic properties as compared with known spiropyrans and can be used as molecular photoswitches. The method of production of new compounds and intermediates for preparation thereof are disclosed.

The invention covers new bicyclic bridged [1,3]oksazepine derivatives of the general formula (I) and (II):

##STR00001##

which exhibit enhanced photochromic properties as compared with known spiropyrans and can be used as molecular photoswitches. The method of production of new compounds and intermediates for preparation thereof are disclosed.

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K.sub.d of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K.sub.d of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.